Table of contents

Clinical/translational cancer immunotherapy

• Original research: Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival (28 February, 2022)

  Juliane Manitz, Sandra P D'Angelo, Andrea B Apolo, S Peter Eggleton, Marcis Bajars, Oliver Bohnsack, James L Gulley
• Original research: Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies (25 February, 2022)

  Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Richard D Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A Soo, Michela Maur, Andrew Weickhardt, Jürgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak, David S Hong
• Original research: Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors (25 February, 2022)

  Yang Du, Ye Liu, Di Wang, Hua Bai, Zhijie Wang, Xiran He, Pei Zhang, Jie Tian, Jie Wang
• Original research: Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial (24 February, 2022)

  Scott S Tykodi, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Michael R Harrison, Ivor Percent, Rakesh Singal, Peter Van Veldhuizen, Daniel J George, Thomas Hutson, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
• ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response

  (22 February, 2022)

  Luana Guimaraes de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, Renee L Chin, Lei Feng, Qi Wang, Tomas Z Barrese, Erminia Massarelli, William William, Faye M Johnson, Renata Ferrarotto, Ignacio Wistuba, Cristian Coarfa, Jack Lee, Jing Wang, Cornelis J M Melief, Michael A Curran, Bonnie S Glisson
• Original research: Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis (22 February, 2022)

  Siming Li, Xiaowen Wu, Xieqiao Yan, Li Zhou, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Jie Dai, Yan Kong, Xiongwen Tang, Hui Feng, Sheng Yao, Keith T Flaherty, Jun Guo, Xinan Sheng
• Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations (16 February, 2022)

  Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, Davide Soldato, Joao V Alessi, Filippo G Dall’Olio, Giuseppe L Banna, Sethupathi Muthuramalingam, Samuel Chan, Margarita Majem, Aida Piedra, Giuseppe Lamberti, Elisa Andrini, Alfredo Addeo, Alex Friedlaender, Francesco Facchinetti, Teresa Gorría, Laura Mezquita, Delphine Hoton, Lacroix Valerie, Frank Aboubakar Nana, James Artingstall, Charles Comins, Massimo Di Maio, Andrea Caglio, Judith Cave, Hayley McKenzie, Thomas Newsom-Davis, Joanne S Evans, Marcello Tiseo, Antonio D'Alessio, Claudia A M Fulgenzi, Benjamin Besse, Mark M Awad, David J Pinato
• CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience (16 February, 2022)

  M Lia Palomba, David Qualls, Sebastien Monette, Shenon Sethi, Ahmet Dogan, Mikhail Roshal, Brigitte Senechal, Xiuyan Wang, Isabelle Rivière, Michel Sadelain, Renier J Brentjens, Jae H Park, Eric L Smith
• Original research: Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer (7 February, 2022)

  Philipp Busenhart, Ana Montalban-Arques, Egle Katkeviciute, Yasser Morsy, Chiara Van Passen, Larissa Hering, Kirstin Atrott, Silvia Lang, Jesus Francisco Glaus Garzon, Elisabeth Naschberger, Arndt Hartmann, Gerhard Rogler, Michael Stürzl, Marianne Rebecca Spalinger, Michael Scharl
• Original research: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner (7 February, 2022)

  Dipti Thakkar, Shalini Paliwal, Bhushan Dharmadhikari, Siyu Guan, Lillian Liu, Shreya Kar, Nikhil K Tulsian, Joshua J Gruber, Leah DiMascio, Konrad H Paszkiewicz, Piers J Ingram, Jerome D Boyd-Kirkup
• Original research: Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer (2 February, 2022)

  Puran Zhang, Yun Gu, Hanji Fang, Yifan Cao, Jieti Wang, Hao Liu, Heng Zhang, He Li, Hongyong He, Ruochen Li, Chao Lin, Jiejie Xu
• Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies (2 February, 2022)

  Martina Svenja Lutz, Boris Klimovich, Stefanie Maurer, Jonas S Heitmann, Melanie Märklin, Latifa Zekri, Gundram Jung, Helmut R Salih, Clemens Hinterleitner
• Original research: Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) (1 February, 2022)

  Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, Ryo Toyozawa, Shunichi Sugawara, Hidetoshi Hayashi, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Hideo Saka, Masahide Oki, Hiroshige Yoshioka, Isamu Okamoto, Haruko Daga, Koichi Azuma, Hiroshi Tanaka, Kazumi Nishino, Rie Tohnai, Nobuyuki Yamamoto, Kazuhiko Nakagawa
• Original research: Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment (1 February, 2022)

  Xiwei Wang, Yanmei Zhang, Xiaofeng Mu, Chloe Ran Tu, Yuet Chung, Sai Wah Tsao, Godfrey Chi-Fung Chan, Wing-Hang Leung, Yu-lung Lau, Yinping Liu, Wenwei Tu
• Original research: Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer (7 February, 2022)

  Shingo Maeda, Tomoki Motegi, Aki Iio, Kenjiro Kaji, Yuko Goto-Koshino, Shotaro Eto, Namiko Ikeda, Takayuki Nakagawa, Ryohei Nishimura, Tomohiro Yonezawa, Yasuyuki Momoi